Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Some holiday reading. European consortium exploring Silicon Nitride coating..
Glta,
Life Long Joints EU
Boston,
Reading this, I think its reasonable to assume that this reference to slurry deposition is part of a more technical permanent coating process and not simply the more rudimentary ceramic shell casting process I was referring to. Something well beyond my expertise..
Thanks,
Boston, The slurry would create a shell that is used as a temporary mold in the metal casting process, not permanent part of a composite end material.. my understanding of general process only. No precise knowledge of this industry...fwiw
Boston, This appears to be a reference to ceramic shell casting, meaning the ceramic shell is basically the mold that is formed around the wax form. This mold is then filled with metal and discarded once metal has been cast... different and more basic use of ceramic than some of the other SiNi possibilities you're referring to elsewhere...
Thank you Smokerx!
glta
Dr Bal made a case for the substantial IP that remains with company. I guess reviewing that will have to wait til the transcript is posted. Unless someone took notes..
He also clarified that in looking at many potential scenarios, nobody was interested in both the spine biz and the R&D/manufacturing model...one or the other. This appears to be the continuation of a strategy of focusing on SiN properties and potential, and playing toward one's strengths...
glta
Wow, lots to process this morning!
Interesting excerpts, among many others, from pr:
"Amedica will serve as CTL’s exclusive OEM provider of silicon nitride products."
"Amedica will re-position under a new name that is reflective of the breadth of its technology and potential applications."
glta
Hi boston, I like your last sentence here. Simple as it is, I hadn't quite thought of that, or heard that aspect of a potential merger strategy articulated here. Thanks
"Two companies collaborating and creating a monopoly is bad and would likely lead to an investigation by the DOJ. However two companies creating tech together and licensing is not. "
Go Dr. Sonny Bal!
No gimmicks! Silicon nitride in a class by itself....
glta
Thank you JayDan, for a superb cluster of articles!
Look forward to giving them a closer read soon..
glta
Sorry guys, I've added a little this week. That means crushing disappointment and shareprice plunge is assured! :)
glta
Very interesting. Thank you Boston.
Hi Ash, do you have a link regarding this info?
Thanks,
glta
Thanks Boston for this analysis. Ongoing thanks to you, CL101, Omid for continued digging, and generous posting...
glta
Ha! Great Comment Omid!
Related to price action today, I've been wondering what this 5 day window represents as far as retail buying opportunity. There is a lot of energy (financial incentive) dropping price and holding here, so will some active buying--hoping to catch a possible low--appear today? and what will day 6 bring? Wouldn't it be lovely to watch a buying blitz!
As usual I cant arrive at confident conclusion..but keep nibbling...
glta
Omid, thank you very much for your vigilante tracking of conversions and pricing. Really helpful to have this updated information.
glta
Tighter communication between CEO and spine division. The rest is guesswork.. a minor point.
glta
Bryan Hansen excerpt from last report:
"Consequently, the following individuals now report directly to me. Aure Bruneau, who is the group President of our Spine and CMF businesses; Pedro Malha, who is the Group Division head of our Dental business; and Angela Main, our Chief Ethics and Compliance Officer."
Totally agree with this Boston. I've been waiting for the wrapper to come off this project, and like you aware of the obvious lack of news or updates.
glta
Regarding annual meeting:
"As of May 11, 2018, the record date, there were 4,422,678 shares of our Common Stock outstanding and entitled to vote. Each share of our Common Stock that you own entitles you to one vote."
Interesting that the offering closed on May 14, meaning no possible votes in the upcoming annual meeting are coming from purchases of the recent offering--even if some of the preferred's or warrants were immediately converted to commons.
glta
Thanks Omid, Interesting perspectives. Liked to see this was a common shareholder for several prior years--Im curious how many preferred owners similiarly have past holdings vs new investors. Difficult to see where the near term interests with the common shareholders--now holding a small slice of the pie--align.
Thanks for taking the time to share this
glta
Nice find Boston! This text is right on point...
Boston,
who willingly gives up their preferreds for a %25 gain, when holding could reap much higher payout?
glta
Omid,
Thanks for this very informative post. I was also thinking that the number of warrants would not adjust down the road, the way the preffereds are capable of doing, so I appreciate your careful read of this matter. Also I've reread CL101s post and agree if he's right, then there is a significantly increased likelyhood that a merger valuation toward the high end of estimates could occur. My biggest worry is the unrestrained share grab that could still continue to unfold. A nice piece of pie has become a sliver, and hopefully wont end up being a crumb when all is done. (Unless its turns into a really, really, really big pie.)
glta
Hey Omid, What happened to your "best case/worst case" post that Boston is responding to here. Are you rethinking it? (post 16332)
glta
I think thats likely, unless, we are hit with addition filings to further dilute...
CL101's assessment feels about right regarding how they could productively spread around 14m, prior to possible m&a--but doesn't address the dark cloud of dilution that is sweeping over us..
Still money to made here..imo, but the big fish are rapidly appearing bigger and bigger..
glta
No, I think this means the warrants are issued simultaneously to the preferreds, and instantly regarded as separated entities from the preferreds, and thereafter follow the warrant terms spelled out in the offering. No ongoing relation to preferreds from the moment they are issued. IMO
glta
I belive this speaks to your question:
"The units will not be certificated and the shares of Series B Preferred Stock and the Warrants comprising such units are immediately separable and will be issued separately in this offering".
glta
Thanks Xena, I thought I'd ask. "designed to be a fail" is nice description.
glta
Thanks KMT1, Can you post a screenshot of those figures? I'd be curious to see short percentages in recent days, but don't know how or where to access daily info.
Interesting day for sure, but I wonder how many buyers understand that share price is still utterly disconnected from the intrinsic value of Amedica and Silicon Nitride biomaterial platform. I'd feel the same way at 10, 20, or $30/share.
glta
I have to disagree MatMar, this news release confirmed that 4 separate multi-year studies, are all meeting endpoints, or exceeding them. This is additional, significant confirmation of that the core narratives of this company are fully on track. Each of these results could be pr'd separately and probably would be under normal circumstances, imo. More confirmation that Amedica and silicon Nitride is indeed a big deal..
glta
To my eyes, this looks like 4 very positive and substantial, pr worthy accomplishments wrapped into one research update. In that way it appears as a rather low-ball way to release a lot of fantastic news. I'll mention again that amda 2018 pr's are forming a very impressive line-up of achievements.. Congrats to S. Bal and the r&d crew..
glta
agreed!
Nothing specific Boston--loose connections between dots. But, I could easily imagine all of this recently assembled talent swinging into action around Hansen if ZBH made a move on acquiring, say, a new biomaterial platform with strong initial focus on Spine and Dental. But what do I know?
glta
Note the additions and changes to the leadership team that Hansen speaks of below. I would like to know more about what projects this interesting pool of talents and connections is working on at Zimmer.
glta
=======================
Bryan Hansen:
https://finance.yahoo.com/news/edited-transcript-zbh-earnings-conference-123747254.html
"To that end, I'd like to discuss some of the recent additions and changes I've made to the leadership team since I joined. Since I'm sitting across from Cole right now, I'm going to go ahead and start with him. We've welcomed Cole Lannum as Senior Vice President of Investor Relations, as I'm sure many of you know. In addition, Ken Tripp recently joined Zimmer Biomet from Cardinal Health and has assumed the role of Senior Vice President of Global Operations and Logistics.
I'm also pleased to announce that Rachel Ellingson, the former Head of Strategy for St. Jude, will be joining us as the Senior Vice President of Strategy.
I've also been augmenting our reporting structure to encourage a more inclusive and responsive organization that is more deeply in tune with the needs of the business.
Consequently, the following individuals now report directly to me. Aure Bruneau, who is the group President of our Spine and CMF businesses; Pedro Malha, who is the Group Division head of our Dental business; and Angela Main, our Chief Ethics and Compliance Officer."
===========================
Rachel Ellingson
www.linkedin.com/in/rachel-ellingson-0bb01133/
SVP, Strategy at Zimmer Biomet
Greater Minneapolis-St. Paul Area
More actions
Zimmer Biomet
With broad business and healthcare industry experience developed through investment banking and executive leadership roles, I successfully drive strategic and operational initiatives to deliver results. My functional leadership experience includes business development, M&A integration, investor relations, communications, public affairs, and organizational change management.
I am known for skillfully assessing business opportunities, synthesizing core strategies and mobilizing teams to execute against those strategies. I am a persuasive communicator who drives decisions and expedites action by navigating complex situations to resolution, building deep relationships and analyzing competitive and industry dynamics.
Recognized as an authentic leader, I develop high performing teams who know they can take informed risks and will have my support. Peers come to me as a sounding board across a broad array of topics in my capacity serving as the CEO’s right-hand person. I have advised executives and Boards of Directors as they contemplate major decisions including acquisitions, divestitures and raising capital.
Working with dynamic leadership teams who continuously evolve their strategy to lead in their markets, I will drive actionable plans to enhance enterprise value and competitive position.
========================================
Kenneth Tripp
www.linkedin.com/in/kenneth-tripp-71a89674/
SVP Global Operations & Logistics
Zimmer Biomet
Experienced Vice President of Operations with a demonstrated history of working in the medical device industry. Skilled in DMAIC, Operations Management, Manufacturing, Supply Chain, Operational Quality, Medical Devices, Value Stream Mapping, and Lean Management. Strong business development professional with a Master of Business Administration (MBA) focused in Organizational Leadership from Ashford University.
Boston
"However if they announce merger they would need the preferred shares to become blank check as dilution amount would be minimal otherwise."
Sorry, I don't really what you mean here. The offer as currently drawn up doesn't appear at all minimal--but many multiples of current fully converted outstanding share count.
glta
I meant to write ">27m fully converted sharecount.."
Thats my sense too, Boston. There is tremendous dilutive leverage due to the extremely low sp...
Its a sobering exercise to consider a possible M+A scenario with >27m fully diluted sharecount rather than current 6m.
glta